证券代码：000963 证券简称：华东医药 公告编号：2025-109 华东医药股份有限公司 关于2022年限制性股票激励计划首次授予限制性股票第三 个解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2022 年限制性股票激励计划首次授予限制性股票第三个 解除限售条件成就，本次符合解除限售条件的激励对象共计 77 人， 可解除限售的限制性股票数量为 127.512 万股，占目前公司总股本的 0.07%。 2、本次解除限售的限制性股票上市流通日为 2025 年 12 月 10 日。 华东医药股份有限公司（以下简称"华东医药"、"公司"）于 2025 年 11 月 20 日召开第十一届董事会第五次会议，审议通过了《关于 2022 年限制性股票激励计划首次授予限制性股票第三个解除限售期 解除限售条件成就的议案》。根据《上市公司股权激励管理办法》公 司《2022 年限制性股票激励计划》（以下简称"《激励计划》"）的相 关规定及公司 2022 年第一次临时股东大会的授权，公司为符合条件 的激励对象办理了解 ...

Group 1 - Hangzhou is transforming from "policy dividends" to "industry dividends" with a focus on technological innovation, making it a strategic hub for global investors in the life and health industry [1][4] - The city has introduced multiple supportive policies for the life and health industry, including the "Management Measures for Supporting Technology Special Projects in the Development of Biomedicine and Health Industry" [1][2] - Hangzhou's life and health industry has a comprehensive industrial chain covering upstream raw materials and equipment, midstream manufacturing, and downstream applications [5][6] Group 2 - As of 2023, the added value of Hangzhou's life and health industry reached 156.8 billion yuan, with a projected increase of 2.8% to 161.2 billion yuan in 2024 [11][13] - Key districts such as Gongshu, Qiantang, and Lin'an are showing significant growth in the life and health industry, with Gongshu's added value reaching 30.3 billion yuan in 2024 [13] - The number of registered enterprises in Hangzhou's life and health industry has been fluctuating, with 121 new enterprises in 2024 and 128 by November 2025 [15][18] Group 3 - The distribution of life and health enterprises is concentrated in districts like Shangcheng, Gongshu, and Xiaoshan, with Gongshu housing major companies such as East China Pharmaceutical and AstraZeneca [20] - Hangzhou has established several industrial parks and clusters, such as Liangzhu Life Science Technology Town and Zijin Port Technology City, to support the life and health industry [23] - The financing landscape for the life and health industry in Hangzhou is active, with a significant number of investments occurring in Qiantang District [26][32] Group 4 - The life and health industry in Hangzhou is seen as a key area for high-quality economic development, with substantial market potential and investment value [32] - Districts are formulating development strategies for the life and health industry, with Qiantang aiming for a total output value of 50 billion yuan by 2026 [34] - The industry benefits from strong policy support, a concentration of leading enterprises, and the establishment of multiple industrial clusters [34]

Core Viewpoint - The company emphasizes its commitment to internationalization and aims to expand its presence in global markets across various sectors, including pharmaceuticals, medical aesthetics, and industrial microbiology [1] Group 1: Pharmaceutical Sector - The pharmaceutical segment has begun exporting certain formulation products to international markets [1] - The innovative drug business is focusing on strengthening independent research and development while actively exploring business development opportunities in collaboration with global peers [1] Group 2: Medical Aesthetics Sector - The medical aesthetics division operates globally, with a marketing network covering over 80 countries and regions [1] - The company has more than 20 products already launched in domestic and international markets, along with over 10 innovative products under development [1] - The goal is to become a leading provider of comprehensive solutions in the global medical aesthetics market [1] Group 3: Industrial Microbiology Sector - The industrial microbiology segment is continuously expanding its overseas market presence [1] - The company has established partnerships with several foreign pharmaceutical companies for specialty raw materials, intermediates, and xRNA business, leading to stable sales growth and a steady increase in customer numbers [1]

Group 1 - The meeting highlighted the mixed economic environment for the upcoming year, with both strategic opportunities and risks being discussed [1][4] - Participants included prominent figures from various industries, such as the chairman of Zhejiang Geely Holding Group and the president of Alibaba Group Tmall, indicating a diverse representation of Zhejiang's advantageous industries [2][4] - The automotive sector, particularly electric vehicles, showed strong growth with Zhejiang's production reaching 509,800 units in the first half of the year, ranking fourth nationally [2][3] Group 2 - Despite the booming market, companies expressed caution regarding future growth, with predictions indicating a shift to a more competitive landscape by 2026 [3] - The local economy in Yiwu demonstrated resilience, with a market transaction volume exceeding 250 billion yuan from January to October, reflecting a 14.8% year-on-year increase [4] - Businesses reported rising production costs and shrinking profits, alongside a trend of shorter-term orders, signaling potential challenges ahead [4] Group 3 - The meeting underscored the importance of identifying new opportunities amid global economic uncertainties, with predictions of continued expansion in the global digital content consumption market [5] - Companies like NetEase reported a 7.2% year-on-year revenue growth, driven by successful digital products, indicating a shift towards cultural industries as a new growth area [5][6] - The trend of service consumption is emerging, with new retail models providing rapid delivery solutions, showcasing adaptability in changing consumer demands [7] Group 4 - Artificial intelligence was a focal point, with companies recognizing its potential to enhance product innovation, smart manufacturing, and operational management [8] - The shift towards a comprehensive competitive landscape involving hardware, software, and AI was noted, emphasizing the need for companies to leverage AI technologies for operational optimization [8] - Experts highlighted the rapid growth of emerging industries driven by innovation, suggesting that AI will play a crucial role in economic growth moving forward [8]

Group 1 - The event "Future Industry Special Session of Science Café: Construction and Application of Synthetic Biology Pilot Platforms" was held in Hangzhou, gathering nearly 50 representatives from government, pilot platforms, enterprises, investment institutions, and research institutes to discuss the construction of pilot platforms in synthetic biology manufacturing and industry collaboration development [1][2] - The pilot platform serves as a crucial bridge between laboratory research and large-scale production, providing engineering and product validation to mitigate technology transfer risks and support industrial implementation [1][2] - The Ministry of Industry and Information Technology announced the first batch of 43 selected pilot platforms nationwide, with three units from Zhejiang, including the National Science Wenzhou Research Institute, Zhejiang Marine Development Research Institute, and Hangzhou Chuanhua Technology City Co., Ltd [1][2] Group 2 - Representatives from the three selected units shared their experiences, highlighting the comprehensive innovation service capabilities of the National Science Wenzhou Research Institute's CDMO platform, the marine biological manufacturing pilot platform's capabilities at Zhejiang Marine Development Research Institute, and the integrated "concept verification - pilot - small-scale production" platform at Hangzhou Chuanhua Technology City [2] - The joint notice from the Ministry of Industry and Information Technology and the National Development and Reform Commission aims to cultivate over 20 pilot capacity construction platforms by 2027, serving more than 200 enterprises and incubating over 400 products to support the transition from innovation to industrial application [2] - The demand for specialized pilot platforms is increasingly urgent due to policy incentives and market needs, as evidenced by discussions at the event regarding the challenges and considerations in building these platforms from an industry perspective [3]

Financial Engineering Research - The Q4 style rotation model indicates signals for small-cap and growth stocks, with recommended sectors including power equipment and renewable energy [2][4] - The dual-driven rotation strategy for Q4 yields a composite score of -1, predicting a preference for small-cap stocks [4] - The value-growth rotation strategy for Q4 shows a composite score of -3, indicating a preference for growth stocks [4] Biopharmaceutical Research - Continuous recommendation for innovative drugs and medical devices along the industry chain [5][6] - Maintain "overweight" ratings for A-share stocks such as Heng Rui Medicine, Ke Lun Pharmaceutical, and others, included in the December monthly portfolio [6][7] - The biopharmaceutical sector underperformed the broader market in November, with a decline of 3.6% compared to a 1.7% drop in the Shanghai Composite Index [7][8] Industry Rotation Insights - In November, the composite factor strategy yielded an excess return of -0.58%, while the single-factor strategy showed an excess return of -0.83% [4] - For December, recommended sectors for the single-factor strategy include banking, construction, non-bank financials, and power equipment [4] - The composite factor strategy recommends sectors such as telecommunications, comprehensive finance, and public utilities [4] Consumer Electronics - The launch of the AI phone assistant by Doubao signifies the upcoming era of AI smartphones, enhancing the hardware ecosystem [20][21] - Doubao's AI assistant can execute complex commands and integrate deeply with operating systems, providing a seamless user experience [21][22] - The assistant's capabilities include cross-application tasks, enhancing user interaction with various platforms [21][22] Medical Commercial Sector - The report maintains an "overweight" rating for leading chain pharmacies, anticipating recovery driven by supply-side clearing and demand-side recovery [15][16] - The retail scale of China's physical pharmacies is projected to reach 611.9 billion yuan in 2024, despite a decline of 1.8% year-on-year [16][17] - The report highlights a recovery trend in drug sales, particularly in essential medicines, amidst a challenging consumer environment [17][18] New Materials Sector - The company achieved a revenue growth of 2.31% year-on-year in the first three quarters of 2025, driven by new materials [27][28] - The company is actively expanding its new materials business, with significant projects underway [28] - The controlling shareholder plans to increase its stake in the company, reflecting confidence in future growth prospects [27][28]

Core Viewpoint - The medical beauty industry in China is experiencing a price war, particularly with the "童颜针" (youthful needle) products, as prices have significantly dropped from over 10,000 yuan to around 5,000-6,000 yuan, indicating a nearly 50% reduction in price [1][3][10]. Industry Trends - The overall growth rate of the Chinese medical beauty market is expected to slow down by 2025, prompting institutions to engage in price competition to attract new customers [3][10]. - The rapid approval of various "童颜针" products has led to increased competition, with nearly 20 companies currently in the registration process for similar products [10][12]. Pricing Strategies - New players like 新氧 (Xinyang) have introduced their "童颜针" at significantly lower prices, with some products priced as low as 2,999 yuan, representing a price drop of 70-80% compared to the market average of over 12,800 yuan [6][10]. - Established brands are also adapting by launching lower-priced variants to capture a broader consumer base, as seen with 圣博玛 (Shengboma) introducing smaller packaging options [8][9]. Market Dynamics - The competition is not only based on price but also on product differentiation and marketing strategies, as companies are now focusing on specific consumer segments [12][14]. - The shift in pricing strategies reflects a broader trend in the medical beauty sector, where companies are increasingly required to justify their prices through quality and service rather than relying solely on brand prestige [12][15]. Consumer Insights - The target demographic for medical beauty services is primarily urban women aged 25-45, with a growing acceptance of mid-range pricing for services, indicating a shift in consumer behavior towards value for money [14][15]. - Consumers are becoming more discerning, considering factors such as product authenticity and the experience of the injecting physician, which adds complexity to the marketing strategies of medical beauty institutions [14][15].

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [2] Core Views - The pharmaceutical and biotechnology industry index experienced a decline of 4.40%, ranking 23rd among 31 primary industries, underperforming the CSI 300 index which fell by 2.19% [6][18] - The valuation of the pharmaceutical and biotechnology industry as of November 28, 2025, is a PE (TTM overall method, excluding negative values) of 29.46x, down from 30.89x in the previous period, indicating a downward trend and below the average [22] - The report highlights potential beneficiaries from the upcoming ASH data, particularly in blood diseases and companies with solid grassroots channels, as well as those with differentiated advantages in oncology, autoimmune, and rare disease products [10] Summary by Sections Industry Review - The pharmaceutical and biotechnology industry index fell by 4.40%, with chemical preparations and medical devices showing declines of 2.86% and 2.95% respectively, while offline pharmacies and vaccines saw larger declines of 8.22% and 6.42% [6][18] - The PE ratio for the pharmaceutical and biotechnology industry is 29.46x, with the highest valuations in the vaccine (47.56x), hospital (41.17x), and medical device (36.77x) sectors, while pharmaceutical circulation has the lowest at 14.58x [22] Important Industry News - The National Administration of Traditional Chinese Medicine and the National Healthcare Security Administration released a directory for traditional Chinese medicine diseases suitable for disease-based payment [26][27] - AstraZeneca's drug "Durvalumab" received FDA approval for a new indication in perioperative treatment of gastric cancer [32] - Otsuka Pharmaceutical's new drug for IgA nephropathy, "Sibeprenlimab," has been approved by the FDA [38] - Bayer's first-in-class lung cancer drug "Sevabertinib" has been approved by the FDA for specific patient populations [40] Investment Recommendations - Focus on innovative pharmaceutical companies that may benefit from the medical insurance or commercial insurance directories, blood cancer targets with imminent ASH data releases, and biotech and CXO leaders with solid technology platforms and international collaboration expectations [10]

整理 | GLP1减重宝典内容团队 当国际巨头在短短数年内把减肥药变成"千亿美金"赛道，中国市场却仍处于起步阶段——渗透率不到1%。在诺和诺德和礼来两大外资 寡头加速推进多靶点与口服剂型的同时，国内一批企业凭借差异化策略发起追赶。全球研发进入"下半场"，技术迭代、成本和政策将决 定下一轮胜负。 ▍双寡头的实力与节奏：销售、临床、口服化三条战线同时推进 按国际研究机构估算，全球GLP-1/减肥药市场在未来数年仍将保持高速增长，且口服剂型与适应症扩展（如MAFLD、OSA等）会进一 步放大市场规模。与此同时，中国庞大的超重/肥胖人口代表着巨大的未被满足需求：现阶段中国肥胖/减重药物的处方渗透率远低于美 国（美国肥胖人群用药率已接近两位数），中国市场仍处于"从0到1"的放量窗口期。多家机构与咨询报告预计，中国GLP-1市场在2030 年前后将迎来数十亿至数百亿人民币规模的增长。 诺和诺德与礼来已经把GLP-1从糖尿病药拓展为肥胖管理的核心工具。2025年前三季度，诺和诺德司美格鲁肽组合实现了数十亿美元级 别的销售，成为公司收入主力；礼来凭借替尔泊肽实现了更高增速，季度及累计业绩显著上扬。两家的临床与商业节奏互为推动 ...

Summary of GLP-1 Market Conference Call Industry Overview - The GLP-1 market is experiencing rapid expansion, with leading company Eli Lilly's market capitalization increasing nearly sixfold over the past five years, surpassing $1 trillion [1][2] - The market for GLP-1 drugs is projected to grow from $2.9 billion in 2015 to nearly $50 billion by 2024, with an annual growth rate of 47% [1][6] Key Points and Arguments - **Market Performance**: In 2024, global sales for semaglutide and tirzepatide are expected to approach $50 billion, continuing strong growth [2] - **Future Trends**: The GLP-1 sector is anticipated to be one of the most focused areas in pharmaceuticals, with each drug iteration potentially doubling market size within 3 to 5 years [3] - **Drug Competition**: Tirzepatide's prescription volume has recently surpassed that of semaglutide, with combined sales exceeding $10 billion in Q3 2025 [7] - **Growth Drivers**: The primary growth will come from expanding usage among individuals with mild obesity, as current prescription rates for GLP-1 drugs in diabetes are around 7% globally and 19% in the U.S., while weight loss indications have a penetration rate of less than 0.5% [8][10] Important but Overlooked Content - **Policy Changes**: Recent adjustments in U.S. Medicare policy will significantly reduce out-of-pocket costs for obesity medications, potentially increasing market volume for new drugs like Ofev and high-dose oral semaglutide [10][11] - **Market Dynamics**: The U.S. market has seen substantial consumer education regarding weight loss medications, which will facilitate the commercialization of new oral weight loss drugs [11] - **Differentiation Strategies**: Companies can achieve differentiation through target combination strategies or by developing oral formulations that improve patient compliance [13][15] - **Domestic Market Potential**: The Chinese weight loss drug market is expected to grow rapidly, driven by a large overweight population and a shift towards self-funded purchases due to limited insurance coverage [25][26] Conclusion - The GLP-1 market is poised for significant growth driven by new drug developments, policy changes, and increasing consumer awareness. Companies in this space, particularly those focusing on oral formulations and innovative treatment strategies, are likely to benefit from these trends.